| Literature DB >> 23622254 |
Moussa S Diarra1, Glenn Block, Heidi Rempel, B Dave Oomah, Judy Harrison, Jason McCallum, Simon Boulanger, Éric Brouillette, Mariza Gattuso, François Malouin.
Abstract
BACKGROUND: Cranberry fruits possess many biological activities partly due to their various phenolic compounds; however the underlying modes of action are poorly understood. We studied the effect of cranberry fruit extracts on the gene expression of Staphylococcus aureus to identify specific cellular processes involved in the antibacterial action.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23622254 PMCID: PMC3641957 DOI: 10.1186/1472-6882-13-90
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
Genes up- and down-regulated for at least two of four strains following a 30-min exposure to the cranberry product NC90 (2 mg/mL)
| | | | |||||||||
| | | | | | | | | | |||
| 0263 | | Peptidoglycan hydrolase | 15.0 | 24.5 | 3.6 | 9.8 | + | = | = | = | |
| 1066 | Fmt protein | 6.8 | 3.8 | 2.9 | 2.0 | + | + | + | + | + | |
| 1459 | | Methionine sulfoxide reductase | 2.3 | 6.0 | −1.5 | 1.2 | = | + | + | + | |
| 1490 | Penicillin binding protein 2 | 2.5 | 2.8 | 1.0 | 1.9 | + | + | + | + | + | |
| 1777 | Putative serine protease Htra | 4.6 | 8.9 | 1.0 | 2.1 | + | + | + | = | | |
| 1932 | | Transglycosylase domain protein | 8.5 | 6.8 | 2.2 | 2.5 | + | = | = | + | + |
| 1942 | DNA-binding response regulator | 8.8 | 10.9 | nd | 2.7 | + | + | + | = | + | |
| 1943 | Sensor histidine kinase VraS | 14.2 | 10.5 | 7.6 | 4.0 | + | + | + | + | + | |
| 1944 | | Hypothetical protein | 5.1 | 7.5 | 1.3 | 1.4 | + | + | + | + | + |
| 2017 | Chaperonin | nd | 2.2 | 2.3 | 2.2 | + | + | + | = | | |
| 2116 | UDP-N-AcGlc-1-carbotransferase | 4.0 | 7.6 | 2.5 | 2.6 | + | + | + | + | + | |
| 2291 | | Staphyloxanthin biosynthesis | 6.0 | 2.2 | 4.5 | 3.9 | – | – | – | = | |
| 2352 | TcaA protein | 5.1 | 6.3 | 1.1 | 1.4 | + | + | + | + | + | |
| 2584 | Immunodominant antigen A | 2.1 | 1.8 | 2.3 | 2.1 | = | = | = | = | | |
| | | | | | | | | | |||
| 0095 | IgG binding protein | −33.3 | −2.0 | −37.5 | nd | – | = | = | | | |
| 0096 | Accessory regulator | −2.0 | −2.9 | −2.7 | −2.2 | – | – | – | | | |
| 0136-0150e | Capsular polysaccharide | −4.9 | nd | −3.1 | −1.9 | – | = | – | | | |
| 0317 | | Lipase precursor | −8.6 | −6.8 | −4.1 | −1.7 | – | – | = | | |
| 451-452e | Alkyl hydroperoxide reductase | −3.4 | −3.6 | −8.2 | −1.2 | = | = | – | | | |
| 0679 | | Na+/H+ antiporter, MnhA | −4.5 | −10.0 | −13.0 | −25.0 | = | = | = | | |
| 0688-0690e | ABC transporter | −43.5 | −66.7 | −86.7 | −91.7 | – | = | = | | | |
| 0765-0766e | Sensor/Histidine kinase | −1.5 | −3.7 | −1.5 | −3.6 | = | = | = | | | |
| 1072 | THF dehydrogenase | −2.1 | −2.6 | −2.7 | nd | = | = | = | | | |
| 1079 | amidophosphoribosyltransferase | nd | −10.0 | −0.8 | −2.6 | = | – | – | | | |
| 1140 | Heme-iron transport | −5.3 | −2.1 | −2.9 | nd | – | = | = | | | |
| 1158-1160e | Succinate dehydrogenase | −5.1 | −7.9 | −4.5 | −3.8 | – | – | = | | | |
| 1173 | Alpha-hemolysin | −3.6 | −4.3 | nd | −2.6 | – | = | = | | | |
| 1262-1263e | Succinyl-CoA synthetase | −5.6 | −3.1 | −6.4 | −2.3 | = | = | = | | | |
| 1328 | Glutamine synthetase repressor | −3.7 | −6.3 | −3.4 | −5.3 | – | – | = | | | |
| 1329 | Glutamine synthetase FemC | −2.7 | −4.2 | −3.2 | −2.9 | – | = | = | | | |
| 1368 | Catalase | −3.2 | −2.4 | −5.2 | −2.1 | = | + | = | | | |
| 1385 | Aconitate hydratase | −3.4 | −3.0 | −6.3 | nd | = | = | = | | | |
| 1396 | FmtC protein | −0.9 | −2.4 | −2.0 | nd | – | – | – | | | |
| 1448-1449e | 2-oxoglutarate dehydrogenase | −8.1 | −5.4 | −4.8 | −4.9 | = | = | = | | | |
| 1741 | Isocitrate dehydrogenase, NADP | −5.6 | −2.2 | −11.5 | −2.5 | = | = | + | | | |
| 1742 | Citrate synthase | −6.7 | −2.3 | −14.3 | −2.2 | = | = | + | | | |
| 1743 | | Amino acid permease | −3.1 | −1.2 | −4.8 | −1.5 | = | = | = | | |
| 2055 | Anti-sigma B factor | −2.6 | nd | −1.6 | −2.1 | – | = | – | | | |
| 2057 | Sigma factor B regulator protein | −1.3 | −3.1 | −0.9 | −2.1 | = | = | – | | | |
| 2066-2068e | Potassium-transporting ATPase | −3.5 | nd | −2.3 | −1.7 | = | = | = | | | |
| 2293 | | NAD/NADP dehydrogenase | −2.0 | −2.4 | −1.3 | nd | – | = | – | | |
| 2694 | lipase | −27.3 | −4.3 | −20.0 | nd | = | = | = | |||
a Data are expressed in log2 ratios of Cy5(cranberry-treated)/Cy3(untreated control); see material and methods.
b Up (+) or down (−) expression of the indicated gene by exposure to daptomycin (DAP), vancomycin (VAN) or oxacillin (OXA), as reported by Muthaiyan et al. [29]; the equal sign (=) indicates genes that were not affected.
c Up (+) or down (−) expression of the indicated gene by exposure to oxacillin (O), bacitracin (B) and D-cycloserine (C) as reported by Utaida et al. [30]; the equal sign (=) indicates genes that were not affected.
d The plus sign (+) indicates genes known to be regulated by the two-component response regulator VraSR following a cell wall stress [42].
e To avoid repetition, the fold modulation of genes arranged in operons is represented as an average for the indicated gene set.
Figure 1qPCR analysis of transcriptional modulations induced in strain ATCC 29213 by the cranberry product NC90 or fraction FC111.
Figure 2Comparison of the inhibitory effect of a variety of molecules on macromolecular biosyntheses in ATCC 29213. Chloramphenicol (Panel A, CHL), norfloxacin (Panel B, NOR), rifampicin (Panel C, RIF), vancomycin (Panel D, VAN), and the cranberry fraction FC111 (Panel E). For A-D, a one-way analysis of variance (ANOVA) with Dunnett’s post test was performed where the macromolecule’s biosynthesis associated to the test antibiotic served as comparator for the three others (*, P <0.05; ***, P<0.001). In E, a two-way ANOVA with Bonferroni’s post test was performed (*, P<0.05; **, P<0.01).
Minimal inhibitory concentrations (MIC) of amoxicillin and oxacillin alone or in combination with increasing concentrations (0 to 256 μg/ml) of the cranberry PC fraction FC111 against ATCC 29213 and MRSA COL
| | | |||||
| ATCC 29213 | amoxicillin | 0.06 | 0.06 (1×) | 0.06 (1×) | 0.015 (4×) | 0.015 (4×) |
| MRSA COL | | 512 | 4 (128×) | 4 (128×) | 1 (512×) | 1 (512×) |
| ATCC 29213 | oxacillin | 0.5 | 0.06 (8×) | 0.03 (16×) | 0.03 (16×) | 0.03 (16×) |
| MRSA COL | 512 | 256 (2×) | 128 (4×) | 32 (16×) | 16 (32×) | |
a Combination of 128 or 256 μg/mL of FC111 with either antibiotic yielded FIC indices of ≤0.25 against all tested strains.
Figure 3kill-curve kinetics evaluated in cation-adjusted Mueller Hinton broth containing FC111 alone or in combination with the specified antibiotic. Panel A, FC111 alone (at its MIC, 1 mg/mL) or in combination with a sub-MIC (1/8 x MIC) of amoxicillin against S. aureus strain Newbould, and Panel B, with a sub-MIC (1/512 x MIC) of oxacillin against MRSA COL. Values are means of duplicates of two separate experiments. Bars represent standard deviations (SD).
Figure 4Bacterial counts (CFU) obtained from mice mammary glands 10h post-infection with Mice mammary glands were treated (intra-mammary administration) 4h after infection with PBS with or without amoxicillin (AMO), the cranberry fraction FC111 (FC) or a combination of both at the indicated concentration (mg/mL). Each dot represents the CFU of each individual gland (n= 6–8) and the median value for each group is indicated by the bar. Statistical differences (P<0.05) between CFU recovered from treated and untreated animals are shown (non-parametric Kruskal-Wallis ANOVA with Dunn's post test).
Figure 5C18 reversed-phase HPLC chromatogram of laboratory scale fraction FC111, displaying separation of 44 constituents. Retention time is in minutes, and absorbance measured at 254 nm (mAU). Alpha numeric labels refer to peaks discussed in the main text, and summarized in Table 3.
Laboratory scale cranberry fraction FC111 constituents separated and characterized by HPLC-DAD-MS.
| 1a,b | 4.8 | | 192 | quinic acid | |
| | | ||||
| 2a,b | 6.5 | 235 | 390 | monotropein | 18.5 ± 0.78% |
| 3 | 7.3 | 235 | 392 | 6,7-dihydromonotropein | 26.8 ± 0.07% |
| 16b | 14.4 | 235 | 416 | unknown monotropein derivative | 54.8 ± 0.99% |
| | | | | Total (vs. A254 nm) | 22 % |
| 4 | 8.7 | 280 | 220 | unknown benzoic acid derivative | 3.1 ± 0.51% |
| 5 | 8.9 | 280 | | unknown benzoic acid derivative | 0.52 ± 0.06% |
| 6 | 9.7 | 290 | 162 | unknown benzoic acid derivative | 0.78 ± 0.10% |
| 7 | 9.8 | 290 | | unknown benzoic acid derivative | 1.18 ± 0.11% |
| 8 | 10.4 | 275 | 316 | dihydroxybenzoic acid glycoside | 3.45 ± 0.29% |
| 9a,b | 11.6 | 285, 320 | 342 | caffeic acid glycoside | 3.06 ± 0.45% |
| 10 | 12.0 | 275 | 300 | hydroxybenzoic acid glycoside | 0.72 ± 0.16% |
| 11 | 12.3 | 295, 305 | 326 | coumaric acid glycoside isomer 1 | 14.04 ± 0.49% |
| 12 | 12.4 | 275 | 238 | unknown benzoic acid derivative | 1.45 ± 0.049% |
| 13 | 13.6 | 315 | 326 | coumaric acid glycoside isomer 2 | 15.1 ± 0.40% |
| 14 | 13.8 | 285, 310 | 326 | coumaric acid glycoside isomer 3 | 16.1 ± 0.56% |
| 15 | 14.1 | 295, 325 | | unknown hydroxycinnamic acid | 7.22 ± 0.092% |
| 16a | 14.4 | 280 | 284 | benzoyl-glycoside | 5.44 ± 0.89% |
| 17 | 14.7 | 285, 330 | 356 | ferulic acid-glycoside | 5.59 ± 0.21% |
| 18 | 15.0 | 275 | | unknown benzoic acid derivative | 13.24 ± 0.13% |
| 19 | 15.3 | 280, 330 | 386 | sinapinic acid-glycoside | 7.47 ± 0.28% |
| 20a,b | 16.3 | 280 | | unknown benzoic acid derivative | 1.50 ± 0.69% |
| | | | | Total (vs. A254 nm) | 9% |
| 21 | 16.8 | 525 | 465 | delphinidin-3-O-galactoside | 0.40 ± 0.00% |
| 24 | 18.0 | 518 | 449 | cyanidin-3-O-galactoside | 18.4 ± 0.01% |
| 25 | 18.2 | 525 | 435 | delphinidin-3-O-arabinoside | 0.60 ± 0.03% |
| 26 | 19.0 | 515 | 433 | pelargonidin-3-O-galactoside | 0.28 ± 0.00% |
| 27 | 19.3 | 520 | 419 | cyanidin-3-O-arabinoside | 11.2 ± 0.00% |
| 28 | 19.8 | 520 | 463 | peonidin-3-O-galactoside | 43.3 ± 0.03% |
| 29 | 20.4 | 524 | 493 | malvidin-3-O-galactoside | 7.64 ± 0.00% |
| 31 | 21.1 | 521 | 433 | peonidin-3-O-arabinoside | 15.5 ± 0.01% |
| 33 | 21.6 | 530 | 463 | malvidin-3-O-arabinoside | 1.79 ± 0.00% |
| | | | | Total (vs. A254 nm) | 40% |
| 30 | 20.5 | 370 | 450 | myricetin-3-O-arabinoside | 4.05 ± 0.34% |
| 32 | 21.3 | 360 | 464 | quercetin-3-O-galactoside | 50.2 ± 0.11% |
| 34 | 22.0 | 354 | 434 | quercetin-3-O-xyloside | 7.71 ± 0.00% |
| 35 | 22.3 | 352 | 434 | quercetin-3-O-arabinopyranoside | 3.72 ± 0.02% |
| 36 | 22.8 | 354 | 434 | quercetin-3-O-arabinofuranside | 13.65 ± 0.12% |
| 37 | 23.3 | 352 | 448 | quercetin-3-O-rhamnoside | 2.87 ± 0.01% |
| 38 | 23.6 | 356 | 478 | isorhamnetin-3-O-galactoside | 5.31 ± 0.04% |
| 39 | 24.0 | 360 | 508 | syringetin-3-O-galactoside | 4.70 ± 0.05% |
| 40 | 24.7 | 360 | | unknown flavonol derivative | 0.46 ± 0.02% |
| 41 | 25.0 | 355 | 448 | isorhamnetin-3-O-arabinoside | 1.55 ± 0.01% |
| 42a,b | 25.6 | 355 | 610 | quercetin-3-O-(6”coumaroyl)-galactoside | 2.27 ± 0.04% |
| 43 | 26.1 | 355 | 478 | syringetin-3-O-arabinoside | 2.04 ± 0.04% |
| 44 | 27.5 | 356 | 568 | quercetin-3-O-(6” benzoyl)-galactoside | 1.48 ± 0.02% |
| Total (vs. A254 nm) | 25% | ||||
a tR , retention time of peak (measured in minutes).
b λmax, refers to characteristic UV–VIS absorption maxima (nm) pertinent to identification.
c MW, molecular weight (measured in Daltons).
d Relative abundance reported as percentage with associated standard deviation (based on two separate HPLC runs); iridoids calculated vs. 254 nm; monophenolic acids calculated vs. 280 nm; anthocyanins calculated vs. 520 nm; flavonols calculated vs. 360 nm.